|
|
|
|
|
|
|
Bristol-Myers Squibb Company (BMY)
|
|
51.17 -0.44 (-0.85%)
|
04-20 16:00
|
|
Open:
|
51.62
|
Pre. Close:
|
51.61
|
|
High:
|
51.85
|
Low:
|
51.02
|
|
Volume:
|
11,669,063
|
Market Cap:
|
83664M
|
|
|
|
Stock Price Prediction (Update at 5:00pm est.)
|
|
If
tomorrow:
|
Open
lower
|
Open
higher
|
|
High:
|
52.189 - 52.689
|
52.689 - 52.992
|
|
Low:
|
49.942 - 50.605
|
50.605 - 51.006
|
|
Close:
|
50.436 - 51.507
|
51.507 - 52.154
|
|
|
|
Technical analysis (as of: 2018-04-20 4:27:54 PM)
|
|
Overall:
|
|
|
Stoxline posted a SELL today, same as yesterday. This stock seems to continue bearish move. So you may continue to hold short positions or sell your long positions. You are relatively safe to short or sell now, downward move is expected.
|
|
Target:
|
Six months: 71.44  One year: 78.77
|
|
Support:
|
Support1: 51.02 Support2: 42.45
|
|
Resistance:
|
Resistance1:
61.17 Resistance2: 67.44
|
|
Pivot:
|
58.12
|
|
Moving Averages:
|
MA(5): 52.31 MA(20): 59.28
MA(100): 62.87 MA(250): 60.17
|
|
MACD:
|
MACD(12,26):
-3.32 Signal(12,26,9): -2.30
|
|
%K %D:
|
%K(14,3): 1.48 %D(3): 2.81
|
|
RSI:
|
RSI(14): 17.56
|
|
52-Week:
|
High: 70.05
Low: 51.02 Change(%): -4.4
|
|
Average Vol(K):
|
3-Month: 896480
10-Days 1545157
|
|
|
|
|
|
★
Strong Sell
★★
Sell ★★★
Neutral
★★★★
Buy
★★★★★
Strong Buy
|
|
|
Price, moving averages and
Bollinger Bands
|
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.BMY has closed above bottom band by 9.8%. Bollinger Bands are 243.1% wider than normal. The large width of the bands suggest high volatility as compared to BMY's normal range. The bands have been in this wide range for 4 bars. This is a sign that the current trend might continue.
|
|
|
Headline News
|
|
2018-04-21T09:30:08-04:00
Stocks To Watch: Earnings Blockbusters And Trump Talks Drug Prices
2018-04-20T08:00:00-04:00
3 Things In Biotech, April 19: Let's Talk Genito-Urinary Cancer
2018-04-20T07:43:03-04:00
Key events next week - healthcare
2018-04-19T13:18:28-04:00
Novartis Q1 results weigh on pharma stocks
2018-04-19T08:00:00-04:00
3 Things In Biotech, April 18: Bristol Plows Ahead, Celldex Flops, Alkermes Gets A Surprise
2018-04-18T19:04:48-04:00
I'm Buying Bristol-Myers Down Near 52-Week Lows
2018-04-18T17:49:43-04:00
ASLAN Pharmaceuticals Updates U.S. IPO Plans
2018-04-18T16:15:00-04:00
U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab) in Previously Treated Patients with Small Cell Lung Cancer and Grants Priority Review
|
|
|
Financial Analysis
|
|
Growth
|
|
|
Growth measures the growth of both a company's revenue
and net income. it tells investors how fast a company is growing.
|
|
Profitability
|
|
|
Profitability measures a company’s ability to
generate earnings as compared to its expenses
and other relevant costs.
|
|
Solvency
|
|
|
Solvency measures a company's ability to meet its long-term debts.
Acceptable solvency ratios will vary from industry to industry.
|
|
Efficiency
|
|
|
Efficiency measures the strength of a company's return on invested capital.
It can identify business that are better managed or not.
|
|
Click here to get more fundamental analysis.
|
|
